# Semaglutide Texas: results over the long haul

> Semaglutide Texas follows the size and duration of published results, from weight loss to heart and kidney outcomes and early appetite research.

**The field folio**

A large result deserves a long horizon. Weight, time and health outcomes in a field folio of the published trials.

## Weight loss over time

Texas gives this folio its sense of distance. A dramatic result can register with me as a major milepost while leaving me impatient for the follow-up. How does the effect look when the horizon moves farther away?

Start with [STEP 1: a mean body-weight change of −14.9% with semaglutide versus −2.4% with placebo at 68 weeks](https://pubmed.ncbi.nlm.nih.gov/33567185/), in adults with overweight or obesity without diabetes. I call that substantial. Then turn to [STEP 5, which found sustained weight reduction over 104 weeks](https://pubmed.ncbi.nlm.nih.gov/36216945/) in adults with overweight or obesity. Duration gives the claim another dimension.

The [weight-loss folio](/weight-loss) puts those findings beside the direct comparison with tirzepatide. It also asks where the evidence runs out of road.

## Cardiovascular and kidney trials

The paper that widens the whole subject is [SELECT, a cardiovascular-outcomes trial in 17,604 adults with established cardiovascular disease and overweight or obesity, without diabetes](https://pubmed.ncbi.nlm.nih.gov/37952131/). Semaglutide reduced the composite of cardiovascular death, nonfatal heart attack or nonfatal stroke versus placebo. That gets my attention for a different reason from a change on the scales: the measured outcome concerns serious health events.

[FLOW studied major kidney-disease events in people with type 2 diabetes and chronic kidney disease](https://pubmed.ncbi.nlm.nih.gov/38785209/). The [heart and kidney folio](/heart-and-kidneys) follows those populations separately. I resist turning such specific findings into a general claim about everybody's future health.

## Appetite research and alcohol

There is a smaller, stranger side road. [Rodent experiments traced weight loss through distributed brain pathways](https://pubmed.ncbi.nlm.nih.gov/32213703/); a [human alcohol-use-disorder trial enrolled 48 adults and followed drinking outcomes over 9 weeks](https://pubmed.ncbi.nlm.nih.gov/39937469/). The scale of that human experiment is plainly different from SELECT's.

I'm curious about this extension of the appetite story, with a much shorter leash on my enthusiasm. The [appetite and alcohol folio](/appetite-and-alcohol) follows the actual experiments without assigning them the reach of the larger trials.

## Side effects in context

Benefits do not make the tolerability questions disappear. A [semaglutide safety review describes gastrointestinal effects and increased biliary-disease risk](https://pubmed.ncbi.nlm.nih.gov/34305810/), while [SUSTAIN-6 recorded more diabetic-retinopathy complications in its high cardiovascular-risk diabetes population](https://pubmed.ncbi.nlm.nih.gov/27633186/).

The [side-effects folio](/side-effects) gives those findings room. This site contains no local treatment directory: Texas is the editorial name, and the research discussed here makes no Texas-specific finding. The [reading list](/references) and [about page](/about) complete the folio.

---

Semaglutide Texas is my editorial folio of published research; it operates no business and offers no medical advice.